REGN Regeneron Pharmaceuticals
- 978.180
- -6.460-0.66%
Regeneron Pharmaceuticals News
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 57.6 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Regeneron Pharmaceuticals(REGN.US)$ Officer SCHLEIFER LEONARD S intends to sell 58,771 shares of its common stock on May 14, with a total market value of approximately
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.78%. Currently, Regeneron Pharmaceut
Regeneron Pharma Initiated at Outperform by Evercore ISI Group
Regeneron Pharma Initiated at Outperform by Evercore ISI Group
Evercore ISI Group Initiates Coverage On Regeneron Pharmaceuticals With Outperform Rating, Announces Price Target of $1150
Evercore ISI Group analyst Cory Kasimov initiates coverage on Regeneron Pharmaceuticals with a Outperform rating and announces Price Target of $1150.
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 17.71% Evercore ISI Group → $1150 Initiates Coverage On → Outperform 05/03/2024 -5.32% Cantor F
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
By Colin Kellaher Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Monday the US Food and Drug Administration has accepted for priority review a supplemental biologics license application for Dupixent as an add-o
Regeneron Pharmaceuticals And Sanof's Dupixent (Dupilumab) SBLA Accepted For FDA Priority Review For Treatment Of Adolescents With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammat
Dupixent (Dupilumab) SBLA Accepted for FDA Priority Review for Treatment of Adolescents With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
US stocks closed | The Federal Reserve hawked to suppress US stocks, the NASDAQ fell, the Dow still rose eight times in a row, and the Krypton debut soared more than 34%
S&P has declined in the short term several times. The Dow rose more than 2% this week, the biggest weekly gain in nearly five months. Tesla closed down 2% and fell four times in a row. Nvidia rebounded more than 1% after three consecutive declines, and TSMC's US stock, which saw a sharp increase in sales in April, rose 4.5%.
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 3.2% Over the Past Week
There May Be Reason For Hope In Regeneron Pharmaceuticals' (NASDAQ:REGN) Disappointing Earnings
The market was pleased with the recent earnings report from Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), despite the profit numbers being soft. Our analysis suggests that investors may have noticed
Regeneron Gene Therapy Improves Hearing in Child Deafness
Regeneron Announces Prelim. Data In An ASGCT Presentation Showing DB-OTO Improved Hearing To Normal Levels In One Child Within 24 Weeks, Initial Hearing Improvements Observed In A Second Child At 6-Week Assessment
Regeneron Announces Prelim. Data In An ASGCT Presentation Showing DB-OTO Improved Hearing To Normal Levels In One Child Within 24 Weeks, Initial Hearing Improvements Observed In A Second Child At 6-We
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child With Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a second child (dosed at 4 years of age) at a 6-week assessment.
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,185, according to analysts polled by Capital IQ. Price: 961.12, Change: +2.48, Percent Ch
Apple's $110B Buyback Is Larger Than the Market Caps of 418 S&P 500 Stocks
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:RBC Capital Markets Global Healthcare Conference at
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$222.35K in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Officer McCourt Marion sold 250 shares of common stock on May 1, 2024 at an average price of $889.41 for a total value of $222.35K.Source: Announcement What is sta
Analysis
Price Target
No Data
